1. Home
  2. MS-DRG
  3. MDC 17
  4. DRG 837

MS-DRG 837

CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC

MDC: 17 — Myeloproliferative Diseases & Disorders, Poorly Differentiated Neoplasms

Chemotherapy consist of:

  • DRG 837 - CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC
  • DRG 838 - CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX WITH CC OR HIGH DOSE CHEMOTHERAPY AGENT
  • DRG 839 - CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SDX WITHOUT CC/MCC
  • CC = Complication or Comorbidity
  • MCC = Major Complication or Comorbidity

Chemotherapy

Principal Diagnosis - Pdx

  • C91.00 Acute lymphoblastic leukemia not having achieved remission
  • C91.01 Acute lymphoblastic leukemia, in remission
  • C91.02 Acute lymphoblastic leukemia, in relapse
  • C92.00 Acute myeloblastic leukemia, not having achieved remission
  • C92.01 Acute myeloblastic leukemia, in remission
  • C92.02 Acute myeloblastic leukemia, in relapse
  • C92.40 Acute promyelocytic leukemia, not having achieved remission
  • C92.41 Acute promyelocytic leukemia, in remission
  • C92.42 Acute promyelocytic leukemia, in relapse
  • C92.50 Acute myelomonocytic leukemia, not having achieved remission
  • C92.51 Acute myelomonocytic leukemia, in remission
  • C92.52 Acute myelomonocytic leukemia, in relapse
  • C92.60 Acute myeloid leukemia with 11q23-abnormality not having achieved remission
  • C92.61 Acute myeloid leukemia with 11q23-abnormality in remission
  • C92.62 Acute myeloid leukemia with 11q23-abnormality in relapse
  • C92.A0 Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
  • C92.A1 Acute myeloid leukemia with multilineage dysplasia, in remission
  • C92.A2 Acute myeloid leukemia with multilineage dysplasia, in relapse
  • C93.00 Acute monoblastic/monocytic leukemia, not having achieved remission
  • C93.01 Acute monoblastic/monocytic leukemia, in remission
  • C93.02 Acute monoblastic/monocytic leukemia, in relapse
  • C94.00 Acute erythroid leukemia, not having achieved remission
  • C94.01 Acute erythroid leukemia, in remission
  • C94.02 Acute erythroid leukemia, in relapse
  • C95.00 Acute leukemia of unspecified cell type not having achieved remission
  • C95.01 Acute leukemia of unspecified cell type, in remission
  • C95.02 Acute leukemia of unspecified cell type, in relapse
  • Z08 Encounter for follow-up examination after completed treatment for malignant neoplasm
  • Z51.11 Encounter for antineoplastic chemotherapy
  • Z51.12 Encounter for antineoplastic immunotherapy

Operating / Non-Operating Room Procedures

  • 3E03002 Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach
    * non-operating room procedure code
  • 3E03302 Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
    * non-operating room procedure code
  • 3E04002 Introduction of High-dose Interleukin-2 into Central Vein, Open Approach
    * non-operating room procedure code
  • 3E04302 Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach
    * non-operating room procedure code
  • 3E05002 Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach
    * non-operating room procedure code
  • 3E05302 Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
    * non-operating room procedure code
  • 3E06002 Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
    * non-operating room procedure code
  • 3E06302 Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach
    * non-operating room procedure code
  • 3E0R302 Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach
    * non-operating room procedure code
  • 3E0S302 Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach
    * non-operating room procedure code

* Procedure Code Combination or 'Procedure Clusters' are combinations of procedures, which, when found on a patient record, are treated differently than their consituent codes.